Perspectives on the development of antioxidant antiepileptogenic agents

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 10, 2012, Pages 1015-1027

  Rowles, J ^a   Olsen, M ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

Animal models; Antiepileptogenic; Antioxidant; Antioxidant response element; Hypoxic response element; Nrf2; Prolyl 4 hydroxylase; Reactive oxygen species

Indexed keywords

8 QUINOLINOL DERIVATIVE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTICONVULSIVE AGENT; ANTIOXIDANT; ASCORBIC ACID; CAFFEIC ACID PHENETHYL ESTER; CATALASE; CICLOPIROX; CURCUMIN; GLUTATHIONE TRANSFERASE; HEME OXYGENASE 1; MELATONIN; OXYGEN DERIVATIVE; OXYGENASE INHIBITOR; PENTETRAZOLE; QUINOLONE DERIVATIVE; RAMELTEON; REACTIVE OXYGEN METABOLITE; RESVERATROL; ROFECOXIB; SULFORAPHANE; SUPEROXIDE DISMUTASE;

CELL SURVIVAL; DISEASE MODEL; ELECTROENCEPHALOGRAM; EPILEPSY; EPILEPTIC STATE; EPILEPTOGENESIS; HUMAN; HYPOXIA; MENTAL PATIENT; NERVOUS TISSUE; NEUROPROTECTION; NONHUMAN; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; REVIEW; SEIZURE THRESHOLD;

ANIMALS; ANTICONVULSANTS; ANTIOXIDANTS; BRAIN; DRUG DISCOVERY; EPILEPSY; HUMANS; MODELS, ANIMAL; OXIDATIVE STRESS; PROCOLLAGEN-PROLINE DIOXYGENASE;

EID: 84866464226     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712802762266     Document Type: Review

References (118)

1. Rogers, S. J.; Cavazos, J. E. In: Pharmacotherapy, A Pathophysiologic Approach; DiPiro J. T.; Talbert R. L.; Yee G. C.; Marzke G. R.; Wells B. G.; Posey L. M., Eds.; McGraw-Hill: New York, 2011; pp. 979-1005.
2. McNamara, J. O. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed.; Brunton L. L., Ed.; McGraw-Hill: New York, 2006; pp. 501-525.
3. Berg, A. T.; Berkovic, S. F.; Brodie, M. J.; Buchhalter, J.; Cross, J. H.; van Emde Boas, W. V.; Engel, J.; French, J.; Glauser, T. A.; Mathern, G. W.; Moshe, S. L.; Nordli, D.; Plouin, P.; Scheffer, I. E. Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE commission on classification and terminology, 2005-2009. Epilepsia, 2010, 51(4), 676-685.
4. Blumenfeld, H. From molecules to networks: Cortical/subcortical interactions in the pathophysiology of idiopathic generalized epilepsy. Epilepsia, 2003, 44(Suppl. 2), 7-15.
5. Reid, C.A.; Phillips, A.M.; Petrou, S. HCN channelopathies: Pathophysiology in genetic epilepsy and therapeutic implications.* Br. J. Pharmacol., 2012, 165(1), 49-56.
6. Pitkanen, A.; Bolkvadze, T.; Immonen, R. Anti-epileptogenesis in rodent post-traumatic epilepsy models. Neurosci. Lett., 2011, 497, 163-171.
7. Pitkanen, A. Therapeutic approaches to epileptogenesis - hope on the horizon. Epilepsia, 2010, 51(Suppl. 3), 2-17.
8. Pitkänen, A.; Lukasiuk, K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol., 2011, 10, 173-186.
9. Mani, R.; Pollard, J.; Dichter, M. A. Human clinical trials in antiepileptogenesis. Neurosci. Lett., 2011, 497, 251-256.
10. Williams, P. A.; White, A. M.; Clark, S.; Ferraro, D. J.; Swiercz, W.; Staley, K. J.; Dudek, F. E. Development of spontaneous recurrent seizures after kainate-induced status epilepticus. J. Neurosci., 2009, 29(7), 2103-2112.
11. Temkin, N.R. Preventing and treating posttraumatic seizures: the human experience. Epilepsia, 2009, 50(Suppl. 2), 10-13.
12. Stables, J. P.; Bertram, E.; Dudek, F. E.; Holmes, G.; Mathern, G.; Pitkanen, A.; White, H. S. Therapy discovery for pharmacoresistant epilepsy and for disease-modifying therapeutics: summary of the NIH/NINDS/AES models II workshop. Epilepsia, 2003, 44(12), 1472-1478.
13. Meldrum, B. S.; Rogawski, M. A. Molecular targets for antiepileptic drug development. Neurotherapeutics, 2007, 4(1), 18-61.
14. Bialer, M.; White, H. S. Key factors in the discovery and development of new antiepileptic drugs. Nat. Rev. Drug Discov., 2010, 9(1), 68-82.
15. Devi, P. U.; Manocha, A.; Vohora, D. Seizures, antiepileptics, antioxidants and oxidative stress: an insight for researchers. Expert Opin. Pharmacother., 2008, 9(18), 3169-3177.
16. Barnham, K. J.; Masters, C. L.; Bush, A. I. Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov., 2004, 3, 205-214.
17. Costello, D. J.; Delanty, N. Oxidative injury in epilepsy: potential for antioxidant therapy? Expert Rev. Neurother., 2004, 4(3), 541-553.
18. Hamed, S. A. The multimodal prospects for neuroprotection and disease modification in epilepsy: relationship to its challenging neurobiology. Restor. Neurol. Neuros., 2010, 28, 323-348.
19. Murias, M.; Jager, W.; Handler, N.; Erker, T.; Horvath, Z.; Szekeres, T.; Nohl, H.; Gille, L. Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: tructureactivity relationship. Biochem. Pharmacol., 2005, 69(6), 903-912.
20. Galano, A. On the direct scavenging activity of melatonin towards hydroxyl and a series of peroxyl radicals. Phys. Chem. Chem. Phys., 2011, 13(15), 7178-7188.
21. Tome, A. R.; Feng, D. J.; Freitas, R. M. The effects of alphatocopherol on hippocampal oxidative stress prior to pilocarpineinduced seizures. Neurochem. Res., 2010, 35(4), 580-587.
22. Tome, A. R.; Ferreira, P. M. P.; Freitas, R. M. Inhibitory action of antioxidants (ascorbic acid or α-tocopherol) on seizures and brain damage induced by pilocarpine in rats. Arq. Neuropsiquiatr,2010,68(3), 355-361.
23. Santos, L. F. L.; Freitas, R. L. M.; Xavier, S. M. L.; Saldanha, G. B.; Freitas, R. M. Neuroprotective actions of vitamin C related to decreased lipid peroxidation and increased catalase activity in adult rats after pilocarpine-induced seizures. Pharmacol. Biochem. Behav., 2008, 89, 1-5.
24. Shin, H. J.; Lee, J. Y.; Son, E.; Lee, D. H.; Kim, H. J.; Kang, S. S.; Cho, G. J.; Choi, W. S.; Roh, G. S. Curcumin attenuates the kainic acid-induced hippocampal cell death in mice. Neurosci. Lett., 2007, 416, 49-54.
25. Gupta, Y.K.; Briyal, S.; Chaudhary, G. Protective effect of transresveratrol against kainic acid-induced seizures and oxidative stress in rats. Pharmacol. Biochem. Behav., 2002, 71, 245-249.
26. Silva, L. F. A.; Hoffman, M. S.; Rambo, L. M.; Ribeiro, L. R.; Lima, F. D.; Furian, A. F.; Oliveira, M. R. F.; Roves, L. F. F. The involvement of Na+, K+-ATPase activity and free radical generation in the susceptibility to pentylenetetrazol-induced seizures after experimental traumatic brain injury. J. Neurol. Sci., 2011, 308, 35-40.
27. Arakawa, M.; Ito, Y. N-acetylcysteine and neurodegenerative diseases: basic and clinical pharmacology. Cerebellum, 2007, 6, 308-314.
28. Banach, M.; Gurdziel, E.; Jedrych, M.; Borowicz, K. K. Melatonin in experimental seizures and epilepsy. Pharmacol. Rep., 2011, 61, 1-11.
29. Irani, K. Oxidant signaling in vascular cell growth, death, and survival: A review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ. Res., 2000, 87, 179-183.
30. Morphy, R.; Rankovic, Z. Designing multiple ligands - medicinal chemistry strategies and challenges. Curr. Pharm. Design, 2009, 15(6), 587-600.
31. Ma, X. H.; Shi, Z.; Tan, C.; Jiang, Y.; Go, M. L.; Low, B.C.; Chen, Z. In-silico approaches to multi-target drug discovery: computer aided multi-target drug design, multi-target virtual screening. Pharm. Res., 2010, 27(5), 739-749.
32. Bolognesi, M. L.; Cavalli, A.; Bergamini, C.; Fato, R.; Lenaz, G.; Rosini, M.; Bartolini, M.; Andrisano, V.; Melchiorre, C. Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks. J. Med. Chem., 2009, 52(23), 7883-7886.
33. Tan, D. X.; Manchester, L. C.; Terron, M. P.; Flores, L. J. Melatonin as a naturally occurring co-substrate of quinine reductase-2,the putative MT3 melatonin membrane receptor: hypothesis and significance. J. Pineal Res., 2007, 43(4), 317-320.
34. Spadoni, G.; Bedini, A.; Rivara, S.; Mor, M. Melatonin receptor agonists: new options for insomnia and depression treatment. C. N. S. Neurosci. Ther., 2011, 17(6), 733-741.
35. Fenoglio-Simeone, K.; Mazarati, A.; Sefidvash-Hockley, S.; Shin, D.; Wilke, J.; Milligan, H.; Sankar, R.; Rho, J. M.; Maganti, R. Anticonvulsant effects of the selective melatonin receptor agonist ramelteon. Epilepsy Behav., 2009, 16(1), 52-57.
36. Shirinzadeh, H.; Eren, B.; Gurer-Orhan, H.; Suzen, S.; Ozden, S. ovel indole-based analogs of melatonin: synthesis and in vitro antioxidant activity studies. Molecules, 2010, 15(4), 2187-2202.
37. Dhir, A.; Naidu, P. S.; Kulkarni, S. K. Effect of rofecoxib, a cyclooxygenase- 2 inhibitor, on various biochemical parameters of brain associated with pentylenetetrazole induced chemical kindling in mice. Fund. Clin. Pharmacol., 2006, 20, 255-261.
38. Weber, V.; Rubat, C.; Duroux, E.; Lartigue, C.; Madesclaire, M.; Coudert, P. New 3- and 4-hydroxyfuranones as anti-oxidants and anti-inflammatory agents. Bioorg. Med. Chem., 2005, 13(14), 4552-4564.
39. Golden, T. R.; Patel, M. Catalytic antioxidants and neurodegeneration. Antioxid. Redox Sign., 2009, 11(3), 555-569.
40. Manfredsson, F. P.; Mandel, R. J. Development of gene therapy for neurological disorders. Discov. Med., 2010, 9(46), 204-211.
41. Itoh, K.; Mimura, J.; Yamamoto, M. Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid. Redox Signal., 2010, 13(11), 1665-1678.
42. Lee, J-M.; Johnson, J. A. An important role of Nrf2-ARE pathway in the cellular defense mechanism. J. Biochem. Mol. Biol.; 2004, 37(2), 139-143.
43. Hur, W.; Gray, N.S. Small molecule modulators of antioxidant response pathway. Curr. Opin. Chem. Biol., 2011, 15, 162-173.
44. Adibhatla, R.M.; Hatcher, J. F. Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal., 2010, 12(1), 125-169.
45. Rahman, I.; Biswas, S.K.; Kirkham, P.A. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem. Pharmacol., 2006, 72(11), 1439-1452.
46. Khor, T. O.; Huang, Y.; Wu, T.; Shu, L.; Lee, J.; Kong, A. N. Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs demethylation. Biochem. Pharmacol., 2011, Jul 20, Available at: http://www.sciencedirect.com/science/article/pii/S0006295211005235 [Accessed 8-23-11].
47. Cheung, K. L.; Kong, A.N. Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention. A.A.P.S. J., 2010, 12(1), 87-97.
48. Wang, S.; Penchala, S.; Prabhu, S.; Wang, J.; Huang, Y. Molecular basis of traditional Chinese medicine in cancer chemoprevention. Curr. Drug Discov. Technol., 2010, 7(1), 67-75.
49. Smirnova, N. A.; Haskew-Layton, R. E.; Basso, M.; Hushpulian, D. M.; Pavappilly, J. B.; Speer, R. E.; Ahn, Y. H.; Rakhman, I.; Cole, P. A.; Pinto, J. T.; Ratan, R. R.; Gazarvan, I. G. Development of Neh2-luciferase reporter and its application for high throughput screening and real-time monitoring of Nrf2 activators. Chem. Biol., 2011, 18(6), 752-765.
50. Saw, C. L.; Wu, Q.; Kong, A. N. Anti-cancer and potential chemopreventive actions of ginseng by activating Nrf2 (NFE2L2) anti-oxidative stress/anti-inflammatory pathways. Chin. Med., 2010, 5, 37.
51. Shin, E. J.; Jeong, J. H.; Kim, A. Y.; Koh, Y. H.; Nah, S. Y.; Kim, W. K.; Ko, K. H.; Kim, H. J.; Wie, M. B.; Kwon, Y. S.; Yoneda, Y.; Kim, H. C. Protection against kainate neurotoxicitiy by ginsenosides: attenuation of convulsive behavior, mitochondrial dysfunction, and oxidative stress. J. Neurosci. Res., 2009, 87(3), 710-722.
52. Wen, Z.; Wang, Z.; Wang, S.; Ravula, R.; Yang, L.; Xu, J.; Wang, C.; Zuo, Z.; Chow, M. S.; Shi, L.; Huang, Y. Discovery of molecular mechanisms of traditional Chinese medicinal formula Si- Wu-Tang using gene expression microarray and connectivity map. PloS One, 2011, 6(3), e18278. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065471/pdf/pone.0018278.pdf [Accessed 8-23-11].
53. Chen, J. S.; Huang, P. H.; Wang, C. H.; Lin, F. Y.; Tsai, H. Y.; Lin, S. J.; Chen, J. W. Nrf2-mediated heme oxygenase-1 expression, an antioxidant-independent mechanism, contributes to ntiatherogenesis and vascular protective effects of Ginkgo biloba extract. Atherosclerosis, 2011, 214(2), 301-309.
54. Acker, T.; Acker, H. Cellular oxygen sensing need in CNS function: physiological and pathological implications. J. Exp. Biol., 2004, 207, 3171-3188.
55. Siddiq, A.; Aminova, L. R.; Ratan, R. R. Hypoxia inducible factor prolyl 4-hydroxylase enzymes: center stage in the battle against hypoxia, metabolic compromise and oxidative stress Neurochem. Res., 2007, 32(4-5), 931-946.
56. Sharp, F. R.; Bernaudin, M. HIF1 and oxygen sensing in the brain. Nat. Rev. Neurosci., 2004, 5, 437-448.
57. Sanchez, R. M.; Jensen, F. E. In: Models of seizure and epilepsy; Pitkanen, A.; Schwartzkroin, P. A.; Moshe S. L., Eds.; Elsevier Academic Press: New York, 2005; pp. 323-331
58. Tang, Y.; Lu, A.; Aronow, B. J.; Wagner, K. R.; Sharp, F. R. Genomic responses of the brain to ischemic stroke, intracerebral haemorrhage, kainate seizures, hypoglycemia, and hypoxia. Eur. J. Neurosci., 2002, 15, 1937-1952.
59. Schaller, B. Influences of brain tumor-associated pH changes and hypoxia on epileptogenesis. Acta Neurol. Scand., 2005, 111, 75-83.
60. Klimova, T.; Chandel, N. S. Mitochondrial complex III regulates hypoxic activation of HIF. Cell Death Differ., 2008, 15, 660-666.
61. Guzy, R. D.; Hoyos, B.; Robin, E.; Chen, H.; Liu, L.; Mansfield, K. D.; Simon, M. C.; Hammerling, U.; Schumacker, P. T. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab., 2005, 1(6), 401-408.
62. Girgenti, M. J.; Hunsberger, J.; Duman, C. H.; Sathyanesan, M.; Terwilliger, R.; Newton, S. S. Erythropoietin induction by electroconvulsive seizure, gene regulation, and antidepressant-like behavioral effects. Biol. Psychiatry, 2009, 66(3), 267-274.
63. Byts, N.; Siren, A-L. Erythropoietin: a multimodal neuroprotective agent. Exp. Transl. Stroke Med., 2009, 1, 4. Available at: http://www.ncbi.nlm.ih.gov/pmc/articles/PMC2816866/pdf/2040-7378-1-4.pdf [Accessed 8-23-11].
64. Moore, E.M.; Bellomo, R.; Nichol, A.D. Erythropoietin as a novel brain and kidney protective agent. Anaesth. Intensive Care, 2011, 39(3), 356-372.
65. Kumral, A.; Tuzun, F.; Oner, M. G.; Genc, S.; Duman, N.; Ozkan, H. Eyrthropoietin in neonatal brain protection: the past, the present and the future. Brain Dev. 2010, 33(8), 632-634.
66. Sozmen, S. C.; Kurul, S. H.; Yis, U.; Tugyan, K.; Baykara, B.; Yilmaz, O. Neuroprotective effects of recombinant human erythropoietin in the developing brain of rat after lithiumpilocarpine induced status epilepticus. Brain Dev. 2011, May 18, Available at: http://www.sciencedirect.com/science/article/pii/S0387760411001367 [Accessed 8-23-11].
67. Jun, Y.; JiangTao, X.; YuanGui, H.; YongBin, S.; Jun, Z.; XiaoJun, M.; JianChun, X.; Heng, X.; XiaoXin, Z.; XinXiang, X. Erythropoietin pre-treatment prevents cognitive impairments following status epilepticus in rats. Brain Res., 2009, 1282, 57-66.
68. Brines, M. L.; Ghezzi, P.; Keenan, S.; Agnello, D.; de Lanerolle, N.; Cerami, C.; Itri, L. M.; Cerami, A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. U. S. A., 2000, 97(19), 10526-10531.
69. Chu, K.; Jung, K. H.; Lee, S. T.; Kim, J. H.; Kang, K. M.; Kim, H. K.; Lim, J. S.; Park, H.K.; Kim, M.; Lee, S. K.; Roh, J. K. Erythropoietin reduces epileptogenic processes following status epilepticus. Epilepsia, 2008, 49(10), 1723-1732.
70. Jin, W.; Kong, J.; Lu, T.; Wang, H.; Ni, H.; Wu, J.; Dai, Y.; Jiang, J.; Liang, W. Erythropoietin prevents secondary brain injury induced by cortical lesion in mice: possible involvement of Nrf2 signaling pathway. Ann. Clin. Lab. Sci., 2011, 41(1), 25-32.
71. Lapchak, P. A. Carbamylated erythropoietin to treat neuronal injury: new development strategies. Expert Opin. Inv. Drugs, 2008, 17(8), 1175-1186.
72. Mofidi, A.; Bader, A.; Pavlica, S. The use of erythropoietin and its erivatives to treat spinal cord injury. Mini Rev. Med. Chem., 2011, Jun 27, Available at: http://www.ncbi.nlm.nih.gov/pubmed/21707531 [Accessed 8-23-11].
73. Erbyraktar, S. G.; Sfacteria, G. G.; Xie, Q. W.; Coleman T.; Kreilgaard, M.; Torup, L.; Sager, T.; Ergayraktar, Z.; Gokmen, N.; Yilmaz, O.; Ghezzi, P.; Villa, P.; Frantelli, M.; Casagrande, S.; Leist, M.; Helboe, L.; Gerwein, J.; Christensen, S.; Geist, M. A.; Pedersen, L. O.; Cerami-Hand, C.; Wuerth, J. P.; Cerami, A.; Brines, M. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl. Acad. Sci. U. S. A., 2003, 100(11), 6741-6746.
74. McDonough, M. A.; Li, V.; Flashman, E.; Chowdhury R.; Morh, C.; Lienard, B. M.; Zondlo, J.; Oldham, N. J.; Clifton, I. J.; Lewis, J.; McNeill, L. A.; Kurzeja, R. J.; Hewitson, K. S.; Yang, E.; Jordan, S.; Syed, R. S.; Schofield, C. J. Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2). Proc. Natl. Acad. Sci. U. S. A., 2006, 103(26), 9814-9819.
75. Murray, J. K.; Balan, C.; Allgeier, A. M.; Kasparian, A.; Viswanadhan, V.; Wilde, C.; Allen, J. R.; Yoder, S. C.; Biddlecome, G.; Hungate, R. W.; Miranda, L. P. Dipeptidylquinolone derivatives inhibit hypoxia inducible factor-1α prolyl hydroxylases-1,-2, and -3 with altered selectivity. J. Comb. Chem., 2010, 12(5), 676-686.
76. Warshakoon, N. C.; Wu, S.; Boyer, A.; Kawamoto, R.; Renock, S.; Xu, K.; Pokross, M.; Evdokimov, A. G.; Zhou, S.; Winter, C.; Walter, R.; Mekel, M. Design and synthesis of a series of novel pyrazolopyridines as HIF-1 alpha prolyl hydroxylase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(21), 5687-5690.
77. Choi, D.; Han, J.; Lee, Y.; Choi, J.; Han, S.; Hong, S.; Jeon, H.; im, Y. M.; Jung, Y. Caffeic acid phenethyl ester is a potent inhibitor of HIF prolyl hydroxylase: structural analysis and pharmacological implication. J. Nutr. Biochem., 2010, 21(9), 809-817.
78. Rosen, M.D.; Venkatesan, H; Peltier H.M.; Bembenek, S.D.; Kanelakis, K.C.; Zhao, L.X.; Leonard, B.E.; Hocutt, F.M.; Wu, X.; Palomino, H.L.; Brondstetter, T.I.; Haugh, P.V.; Cagnon, L.; Yan, W.; Liotta, L.A.; Young, A.; Mirzadegan, T.; Shankley, N.P.; Barrett, T.D.; Rabinowitz, M.H. Benzimidazole-2-pyrazole HIF prolyl 4-hydroxylase inhibitors as oral erythropoietin secretagogues. A. C. S. Med. Chem. Lett., 2010, 1(5), 526-529.
79. Smirnova, N.A.; Rakhman, I.; Moroz, N.; Basso, M.; Payappilly, J.; Kazakov, S.; Hernandez-Guzman, F.; Gaisina, I.N.; Kozikowski, A.P.; Ratan, R.R.; Gazaryan, I.G. Utilization of an in vivo reporter for high throughput identification of branched small molecule regulators of hypoxic adaptation. Chem. Biol., 2010, 17(4), 380-391
80. Lee, Y.; Shin, D. H.; Kim, J. H.; Hong, S.; Choi, D.; Kim, Y. J.; Kwak, M. K.; Jung, Y. Caffeic acid phenethyl ester-mediated Nrf2 activation and I kappa B kinase inhibition are involved in NF ppa B inhibitory effect: structural analysis for NF kappa B inhibition. Eur. J. Pharmacol., 2010, 643(1), 21-28.
81. Bernhardt, W. M.; Wiesener, M. S.; Scigalla, P.; Chou, J.; Schmieder, R. E.; Gunzler, V.; Eckardt, K. U. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J. Am. Soc. Nephrol., 2010, 21(12), 2151-2156.
82. Mehdipour, A. R.; Hamidi, M. Brain drug targeting: a computational approach for overcoming blood-brain barrier. Drug Discov. Today, 2009, 14(21-22), 1030-1036.
83. Liu, X.; Chen, C.; Smith, B. J. Progress in brain penetration evaluation in drug discovery and development. J. Pharmacol. Exp. Ther., 2008, 325(2), 349-356.
84. Hansch, C.; Anderson, S. M. The structure-activity relationship in barbiturates and its similarity to that in other narcotics. J. Med.Chem., 1967, 10(5), 745-753.
85. Angelow, S.; Haselbach, M.; Galla, H.J. Functional characterization of the active ascorbic acid transport into cerebrospinal fluid using primary cultured choroid plexus cells. Brain Res., 2003, 988(1-2), 105-113.
86. Loscher, W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus dels of temporal lobe epilepsy. Epilepsy Res., 2002, 50, 105-123.
87. Brown, W. C.; Schiffman, D. O.; Swinyard, E. A.; Goodman, L. S. Comparative assay of antiepileptic drugs by psychomotor seizure test and minimal electroshock threshold. J. armacol. Exp. Ther., 1953, 107(3), 273-283.
88. Barton, M. E.; Klein, B. D.; Wolf, H. H.; White, H.S. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res., 2001, 47, 217-227.
89. Loscher, W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure, 2011, 20, 359-368.
90. Sloviter, R. S. Hippocampal epileptogenesis in animal models of mesial temporal lobe epilepsy with hippocampal sclerosis: the importance of the "latent period" and other concepts. Epilepsia, 2008, 49(Suppl. 9), 85-92.
91. Goodman, J. H. In: Neuropharmacological Methods in Epilepsy Research; Peterson, S. L.; Albertson, T. E., Eds.; CRC Press: Boca Raton, 1998; pp. 95-125.
92. Scroza, R. A.; Arida, R. M.; Naffah-Mazzacoratti, M. D. G.; Scerni, D. A.; Calderazzo, L.; Cavalheiro, E. A. The pilocarpine model of epilepsy: what have we learned? An. Acad. Bras. Cienc., 2009, 8(3), 345-365.
93. Turski, L.; Ikonomidou, C.; Turski, W. A.; Bartolotto, Z. A.; Cavalheiro, E. A. Review: cholinergic mechanisms and epileptogenesis. The seizures induced by pilocarpine: a novel experimental model of intractable epilepsy. Synapse, 1989, 3(2), 154-171.
94. Freitas, R. M. Investigation of oxidative stress involvement in hippocampus in epilepsy model induced by pilocarpine. Neurosci. Lett. 2004, 462, 225-229.
95. Waldbaum, S.; Liang, L.P.; Patel, M. Persistent impairment of mitochondrial and tissue redox status during lithium-pilocarpineinduced epileptogenesis. J. Neurochem., 2010, 115(5), 1172-1182.
96. Pestana, R. R. F.; Kinjo, E. R.; Hernandes, M. S.; Britto, L. R. G. eactive oxygen species generated by NADPH oxidase are involved in neurodegeneration in the pilocarpine model of temporal lobe epilepsy. Neurosci. Lett., 2010, 484, 187-191.
97. Ben-Ari, Y.; Cossart, R. Kainate, a double agent that generates seizures: two decades of progress. Trends Neurosci., 2000, 23, 580-587.
98. Dudek, F. E.; Clark, S.; Williams, P. A.; Grabenstatter, H. L. In: Models of Seizures and Epilepsy; Pitkanen, A.; Schwartzkroin, P. A.; Moshe, S. L., Eds.; Elsevier Academic Press: Boston, 2006; pp. 415-432.
99. Clifford, D. B.; Olney, J. W.; Maniotis, A.; Collins, R. C.; Zorumski, C. F. The functional anatomy and pathology of lithium pilocarpine and high-dose pilocarpine seizures. Neuroscience, 1987, 23(3), 953-968.
100. Vincent, P.; Mulle, C. Kainate receptors in epilepsy and excitotoxicity. Neuroscience, 2009, 158, 309-323.
101. Chuang, Y-C.; Chang, A. Y. W.; Lin, J-W.; Hsu, S-P.; Chan, S. H. H. Mitochondrial dysfunction and ultrastructural damage in the hippocampus during kainic acid-induced status epilepticus in he rat. Epilepsia, 2004, 45(10), 1202-1209.
102. Ueda, Y.; Yokoyama, H.; Niwa, R.; Konaka, R.; OhyaNishiguchi, H.; Kamada, H. Generation of lipid radicals in the hippocampal extracellular space during kainic acid-induced seizures in rats. Epilepsy Res., 1997, 26(2), 329-333.
103. Ueda, Y.; Yokoyama, H.; Nakajima, A.; Nakajima, A.; Tokumaru, J.; Doi, T.; Mitsuyama, Y. Glutamate excess and free radical formation during and following kainic acid-induced status epilepticus. Exp. Brain Res., 2002, 147(2), 219-226.
104. Ueda, Y.; Doi, T.; Tokumaru, J; Nakajima, A.; Nagatomo, K. In vivo evaluation of the effect of zonisamide on the hippocampal redox state during kainic acid-induced seizure status in rats. Neurochem. Res., 2005, 30(9), 1117-1121.
105. Zheng, X-Y.; Zhang, H-L.; Luo, Q.; Zhu, J. Kainic acid-induced neurodegenerative model: potentials and limitations. J. Biomed. Biotechnol., 2011, Article ID 457079, Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992819/?tool=pubmed [Accessed 8-23-11].
106. Glien, M.; Brandt, C.; Potschka, H.; Voigt, H.; Ebert, U.; Loscher, W. Repeated low-dose treatment of rats with pilocarpine: low mortality but high proportion of rats developing epilepsy. Epilepsy Res., 2001, 46(2), 111-119.
107. Goffin, K.; Nissinen, J.; Van Laere, K.; Pitkanen, A. Cyclicity of spontaneous recurrent seizures in pilocarpine model of temporal lobe epilepsy in rat. Exp. Neurol., 2007, 205, 501-505.
108. Hellier, J. L.; Dudek, F. E. Chemoconvulsant model of chronic spontaneous seizures. Curr. Protoc. Neurosci., 2005, Chapter 9, Unit 9.19.
109. Brines, M.L.; Dare, A.O.; Delanerolle, N.C. The cardiac glycoside ouabain potentiates excitotoxic injury of adult neurons in rat hippocampus. Neurosci. Lett., 1995, 191(3), 145-148.
110. Goddard, G. V.; McIntyre, D. C.; Leech, C. K. A permanent change in brain function resulting from daily electrical stimulation. Exp. Neurol., 1969, 25, 295-330.
111. Mody, I. The molecular-basis of kindling. Brain Pathol., 1993, 3(4), 395-403.
112. Bertram, E. The Relevance of Kindling for Human Epilepsy. Epilepsia, 2007, 48(Suppl. 2), 65-74.
113. McIntyre, D. C.; Gilby, K. L. Kindling as a model of human epilepsy. Can. J. Neurol. Sci., 2009, 36(Suppl2), S33-S35.
114. Sato, M.; Racine, R. J.; McIntyre, D. C. Kindling: basic mechanisms and clinical validity. Electroencephalogr. Clin. Neurophysiol., 1990, 76, 459-472.
115. Schmidt, J. Changes in seizure susceptibility in rats following chronic administration of pentylenetetrazole. Biomedica Biochimica Acta, 1987, 46, 267-270.
116. Karlen, R.; Murphy, V.; Colder, L.D.; Turkanis, S. A. Pentylenetetrazole kindling in mice. Neuropharmacology, 1989, 28, 775-780.
117. Pinel, J. P. J.; Rovner, L. I. Experimental epileptogenesis - kindling-induced epilepsy in rats. Exp. Neurol., 1978, 58(2), 190-202.
118. Coulter, D. A.; McIntyre, D. C.; Loscher, W. Animal models of limbic epilepsies: what can they tell us? Brain Pathol., 2002, 12(2), 240-256.